ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Adamts1 Exacerbates Post-Myocardial Infarction Scar Formation via Mechanosensing of Integrin α8.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Targeting ADAMTS1/HDAC6 alleviates TGF-β1/SMAD2-associated cardiac fibrosis in cardiac fibrosis post-myocardial infarction.Cell biology and toxicology · 2026Article
- Adamts1 Exacerbates Post-Myocardial Infarction Scar Formation via Mechanosensing of Integrin α8.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- The Dual Role of ADAMTS1 in Cardiovascular Remodeling: Balancing Extracellular Matrix Homeostasis and Pathological States.Journal of cardiovascular development and disease · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
-Myocardial infarction (MI) remains a leading cause of morbidity and mortality worldwide, with post-infarction cardiac remodeling, particularly excessive scar formation, representing a critical determinant of patient outcomes. However, the mechanistic pathways governing pathological scar formation remain incompletely understood. Here, we demonstrate that ADAMTS1 (A Disintegrin and Metalloproteinase with Thrombospondin Motifs 1), significantly upregulated in endothelial cells (ECs) following MI, plays a pivotal role in regulating cardiac fibroblast activation through a novel mechanotransduction pathway involving integrin α8 (ITGα8). Using EC-specific ADAMTS1 overexpression and knockout mice combined with cardiac fibroblast-specific ITGα8 deletion models, we found that ADAMTS1 overexpression exacerbates cardiac dysfunction and increases scar size, while ADAMTS1 deficiency provides cardioprotection. Mechanistically, ADAMTS1 modulates extracellular matrix stiffness through proteoglycan (PG) cleavage rather than direct protein interactions, which activates ITGα8 mechanosensing specifically in cardiac fibroblasts. Among integrin family members tested, ITGα8 shows selective responsiveness to ADAMTS1-mediated mechanical cues, as confirmed by tunable-stiffness hydrogel experiments and validated through comprehensive proteomic and functional analyses. ITGα8 deficiency rescues ADAMTS1-induced cardiac dysfunction and reduces pathological scar formation. These findings reveal a previously unrecognized ADAMTS1-ITGα8 mechanotransduction pathway, representing a promising therapeutic target for optimizing post-infarction cardiac remodeling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.